Data from Activation of Tumor-Cell STING Primes NK-Cell Therapy
Erik H. Knelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), David A. Barbie(Dana-Farber Cancer Institute), Michael Tolstorukov(Dana-Farber Cancer Institute), Minh Ha(Dana-Farber Cancer Institute), Zehua Li(Dana-Farber Cancer Institute), Neil Lineberry(Institute for Learning and Development), Ha Vo(Dana-Farber Cancer Institute), Saemi Han(Dana-Farber Cancer Institute), Nathaniel Spicer(Dana-Farber Cancer Institute), Thomas P. Albertson(Brigham and Women's Hospital), Arrien A. Bertram(Dana-Farber Cancer Institute), Timothy J. Haggerty(Dana-Farber Cancer Institute), Moataz Noureddine(Dana-Farber Cancer Institute), Pınar Ö. Eser(Broad Institute), Pieter J. Schol(Leiden University Medical Center), Marco Campisi(Dana-Farber Cancer Institute), Kartika Venugopal(Dana-Farber Cancer Institute), Tetsuo Tani(Keio University), Corinne E. Gustafson(Brigham and Women's Hospital), Assunta De Rienzo(Brigham and Women's Hospital), William G. Richards(Brigham and Women's Hospital), Raphael Bueno(Brigham and Women's Hospital), Minyue Chen(Dana-Farber Cancer Institute), Bonje Obua(Dana-Farber Cancer Institute), Cameron Messier(Dana-Farber Cancer Institute), Pasi A. Jänne(Harvard University), Brandon Piel(Dana-Farber Cancer Institute), Adnan O. Abu‐Yousif(Takeda (Japan)), Cloud P. Paweletz(Massachusetts General Hospital), Tran C. Thai(Dana-Farber Cancer Institute), Richard C. Gregory(Institute for Learning and Development), Rizwan Romee(Washington University in St. Louis), Vicky A. Appleman(Takeda (United States)), Matthew A. Booker(Broad Institute), Anna M. Lee-Hassett(Dana-Farber Cancer Institute), Erin Shannon(Broad Institute), Elena V. Ivanova(Massachusetts General Hospital), Patrick H. Lizotte(Harvard University), Ismail Ozgenc(Dana-Farber Cancer Institute), Marina Vivero(Brigham and Women's Hospital), Brittany Meisenheimer(Dana-Farber Cancer Institute), Antja-Voy Hartley(Indiana University School of Medicine), Navin R. Mahadevan(Brigham and Women's Hospital), Mubin Tarannum(Dana-Farber Cancer Institute), Israel Cañadas(Fox Chase Cancer Center), Alexander Parent(Institute for Learning and Development), Ari Zlota(Dana-Farber Cancer Institute), Eric L. Smith(Dana-Farber Cancer Institute), Juan J. Miret(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k